lercanidipine
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
107
Go to page
1
2
3
4
5
July 07, 2025
Lercanidipine-Induced Hyponatremia in Elderly Patients: A Not-So-Rare Complication.
(PubMed, Cureus)
- "Current NHS guidelines do not recommend routine electrolyte monitoring when prescribing CCBs, unlike recommendations for ACE inhibitors and ARBs. We recommend implementing routine electrolyte monitoring when initiating CCBs in this vulnerable population group to prevent potentially life-threatening complications."
Journal • Cardiovascular • Critical care • Geriatric Disorders • Heart Failure • Hypertension
June 13, 2025
SKIN-CKD: The Role of Skin Sodium Accumulation in Chronic Kidney Disease
(clinicaltrials.gov)
- P=N/A | N=60 | Recruiting | Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
New trial • Chronic Kidney Disease • Nephrology • Renal Disease
June 07, 2025
Management of Lercanidipine-induced Lyell's syndrome
(Euroanaesthesia 2025)
- "Pain was managed with patient-controlled analgesia of Morphine, Ketamine and Droperidol plus peripheral analgesia. Hydrotherapy sessions were provided with a combination of Propofol, Ketamine, Dexmedetomidine, and Fentanyl, allowing effective wound care.Patient care involved daily ophthalmology evaluation, pulmonary rehabilitation and oxygen therapy. By the 24th day of hospitalization, the patient showed over 90% healing of the affected skin areas and was discharged home. This case underscores the critical importance of intensive and rigorous care in the management of TEN, particularly in a specialized BU. Rapid disease progression shows the unpredictable nature of this severe drug-induced reaction."
Inflammation • Ophthalmology • Pain • Rare Diseases • Steven-Johnson Syndrome
May 28, 2025
Lercanidipine Enhances Cisplatin Activity: Dual Anticancer and Anti-Inflammatory Effects via Caspase Activation and MAPK Inhibition.
(PubMed, Pharmaceuticals (Basel))
- "It also significantly inhibited MAPK signaling, activated apoptotic caspases, and reduced TNF-α levels, suggesting potential anti-inflammatory activity. These findings highlight lercanidipine's potential for repurposing as an adjunct in cancer therapy."
Journal • Breast Cancer • Cardiovascular • Genito-urinary Cancer • Neuroblastoma • Oncology • Prostate Cancer • Solid Tumor • CASP3 • CASP8 • TNFA
April 10, 2025
Nonsurgical management of pheochromocytoma in the very elderly – a case series and review of the literature
(ESPE-ESE 2025)
- "Blood pressure (BP) treatment was with doxazosin, losartan and bisoprolol...On a follow up of 0.54 years BP was slightly elevated and was controlled with doxazosin, lercanidipine and bisoprolol... in this series of three elderly patients with PCC that did not have an adrenalectomy we found one occurrence of a stroke and one death in the same patient on an average follow up of 5.69 years. It thus seems that medical management may allow satisfactory disease control in select cases in which surgery is not possible or refused by very elderly patients."
Clinical • Review • Cardiovascular • Endocrine Cancer • Oncology • Solid Tumor
April 18, 2025
Warning issued over common blood pressure drug after labelling error
(MSN News)
- "Patients who take a common drug for high blood pressure are being urged to check the medication after its manufacturer reported that a mistake in the strength of the dose had been printed on some packs...One batch of the medicine Lercanidipine, made by Recordati Pharmaceuticals, is labelled as containing 10mg tablets when it in fact contains 20mg....The correct strength is printed on the top of the carton and on the blister strips, according to an alert issued by the Medicines and Healthcare products Regulatory Agency (MHRA)...Patients are being urged to check for the batch number MD4L07 with an expiry date of January 2028 as a 'precautionary measure'."
Commercial • Hypertension
April 12, 2025
Voltammetric determination of lercanidipine in urine, blood plasma, and serum using hollow fiber-based liquid phase microextraction.
(PubMed, Talanta)
- "The calibration dependence of the combined HF-LPME-SWV method was established in the range of 1-1000 nmol L-1, with limits of quantification (LOQ) and detection (LOD) of 3.3 and 1.1 nmol L-1, respectively. The applicability of the developed method was verified by analysis of human urine, blood plasma, and blood serum samples spiked with 20 and 100 nmol L-1 LCN with recoveries ranging from 93.2 to 112.9 % with respective RSDs 1.72-8.5 % (n = 3)."
Journal
February 19, 2025
Looks are deceiving: An uncommon cause of milky white peritoneal dialysis effluent.
(PubMed, Perit Dial Int)
- "We suspended lercanidipine and within a few days the peritoneal dialysis effluent was clear. Currently the patient is well adjusted to the technique and had no further episodes of chyloperitoneum."
Journal • Dyslipidemia • Hypertriglyceridemia
February 07, 2025
UHPLC-MS/MS method for the simultaneous quantification of five calcium channel antagonists' drugs in human plasma.
(PubMed, Biomed Pharmacother)
- "Drug concentrations in the patient's serum or urine (also known as therapeutic drug monitoring, or TDM) and blood pressure measurements following supervised medication ingestion are two techniques for assessing treatment adherence. In alignment with guideline from the Food and Drug Administration (FDA) and European Medicines Agency (EMA), this study aims to design, develop, and validate a single UHPLC method for the plasma quantification of five antihypertensive drugs within the calcium channel blocker class: amlodipine, nifedipine, barnidipine, lercanidipine and lacidipine."
Journal • Cardiovascular • Hypertension
November 26, 2024
Comparative Effectiveness of Lercanidipine and Amlodipine on Major Adverse Cardiovascular Events in Hypertensive Patients.
(PubMed, Am J Hypertens)
- "Lercanidipine demonstrated comparable effectiveness to amlodipine in preventing MACE among hypertensive patients. Given its comparable antihypertensive efficacy and potential for fewer side effects based on prior studies, lercanidipine may be considered a preferable option for hypertension management."
Adverse events • HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Myocardial Infarction
October 23, 2024
SHARK PEDICLE ISLAND FLAP FOR BASAL CELL CARCINOMA OF THE PERIALAR ZONE OF THE NOSE: PHOTOXICITY AND PHOTOCARCINOGENICITY MEDIATED BY POTENTIALLY NITROSAMINE CONTAMINATED DRUG INTAKE -A NEW EXPLANATION FOR THE SKIN CANCERS PATHOGENESIS?
(PubMed, Georgian Med News)
- "We inform about another polymedication intake in a patient with arterial hypertension and diabetes mellitus, which includes the following medications: gliclazide 60 mg once daily and metformin hydrochloride 850 mg once daily, both since 24 years ; sotalol hydrochloride 80 mg since 2 years; bisoprolol fumarate 5 mg since 17 years; candesartan cilexetil/hydrochlorothiazide 16 mg/ 12.5 mg since 2 years; and lercanidipine hydrochloride 20 mg also since 2 years. An optimal postoperative outcome was achieved. This article focuses on the possible role of drug-mediated photo nitrosogenesis/ carcinogenesis of skin cancer by briefly reviewing and analyzing the available literature to date."
Journal • Basal Cell Carcinoma • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Metabolic Disorders • Non-melanoma Skin Cancer • Oncology • Pulmonary Arterial Hypertension • Skin Cancer
August 06, 2024
Annular elastolytic giant cell granuloma: Lesions in non-sun exposed areas, treated with topical dapson, alongside topical steroids
(EADV 2024)
- "The patient ’ s medication history revealed metoprolol, doxazosin, lercanidipine and apixaban...The first biopsy showed urticarial reaction but the patient did not respond to bilastine 20mg/day...Afterwards, we changed the therapy to topical clobetasol propionate lotion %0.05, 2x1 on weekdays and topical dapson %7.5, 1x1, every day, and achieved nearly %90 remission in 4 months (second cycle of therapy)... To conclude, AECGC may be seen in non-sun-exposed areas, and if the suspicion of AEGCG is not indicated to the pathologist in advance, the diagnosis may be overlooked. And topical dapson therapy may be an option in the treatment of the disease, but further research is needed."
Atrial Fibrillation • Dermatology • Dermatopathology • Hematological Malignancies • Immunology • Monoclonal Gammopathy • Rare Diseases • Urticaria • Vasculitis
September 22, 2024
Calcium channel blocker overdose: Not all the same toxicity.
(PubMed, Br J Clin Pharmacol)
- "Dihydropyridines were the commonest CCB overdoses, with amlodipine making up half. More severe toxicity occurred with diltiazem and verapamil."
Journal • Acute Kidney Injury • Critical care • Hypotension • Nephrology • Renal Disease
August 14, 2024
Unveiling the Preparation and Characterization of Lercanidipine Hydrochloride in an Oral Solid Self-Nanoemulsion for Enhancing Oral Delivery.
(PubMed, Cureus)
- "This study successfully prepared LRCH using the promising strategy of SSNEDDS as a hard gelatin capsule with a higher dispersion rate. It improved its stability and expected bioavailability compared to the brand-marketed tablet as the standard."
Journal • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease
July 24, 2024
Anti-inflammatory efficacy of lercanidipine hydrochloride on TNF-α induced HaCaT cells and TPA-induced acute mouse ear inflammation model.
(PubMed, Arch Dermatol Res)
- No abstract available
Journal • Preclinical • Inflammation • TNFA
June 16, 2024
Toxicologic analysis of 35 drugs in post mortem human blood samples with focus on antihypertensive and antiarrhythmic drugs.
(PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
- "Therefore, a novel analytical method was developed and validated for the quantification of 35 drugs with toxicological relevance, including antihypertensive and antiarrhythmic drugs (ajmaline, amlodipine, amiodarone, atenolol, bisoprolol, carvedilol, clonidine, desethylamiodarone, diltiazem, donepezil, doxazosin, dronedarone, esmolol, flecainide, lercanidipine, lidocaine, metoprolol, nebivolol, nimodipine, pindolol, prajmaline, propafenone, propranolol, sotalol, urapidil, and verapamil), as well as other medications commonly found in combination (sildenafil, tadalafil, atorvastatin, clopidogrel, dapoxetine, memantine, pentoxifylline, rivastigmine, and ivabradine). In addition, the method was specifically tested for the use in post mortem analysis. The applicability of our method was demonstrated by the analysis of two authentic human autopsy blood samples."
Journal
June 21, 2024
A pharmacoepidemiological nested case-control study of risk factors for venous thromboembolism with the focus on diabetes, cancer, socioeconomic group, medications, and comorbidities.
(PubMed, Diab Vasc Dis Res)
- "In this cohort, with 50% diabetes prevalence, pancreatic, stomach, lung and bronchus, and ovarian cancers were strongly associated with VTE. Corticosteroids, gabapentinoids, and psychotropic medications had the strongest associations with VTE among medications. This may be valuable for generating hypotheses for the further research. Lercanidipine may be a novel protective medication against VTE."
Journal • Cardiovascular • CNS Disorders • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammatory Bowel Disease • Mental Retardation • Metabolic Disorders • Oncology • Ovarian Cancer • Pancreatic Cancer • Psychiatry • Respiratory Diseases • Solid Tumor • Venous Thromboembolism
March 23, 2024
Calcium-channel blockers chyloperitoneum: an underrated complication in peritoneal dialysis
(ERA-EDTA 2024)
- "All of them were affected by hypertension and 10 of 16 (2 APD and 8 CAPD) were already in chronic therapy with CCBs (5 with lercanidipine, 4 with lacidipine and 1 with barnidipine), all at maximum accepted dosage. cloudy peritoneal effluent is always cause for concern for Nephrologists since that it could represent, event without any other sign or symptom of infection, an already subclinical bacterial peritonitis. Most of dialysis patients are also affected by hypertension. Since usage of ARB and ACE-I is limited by risk of hyperkalaemia, CCBs represents one of the most prescribed antihypertensive drugs."
Cardiovascular • Hypertension • Infectious Disease • Nephrology • Pain • Pancreatitis
March 08, 2024
RENOPROTECTIVE EFFECT OF 3RD GENERATION CALCIUM CHANNEL BLOCKERS
(ISN-WCN 2024)
- "Third generation dihydropyridine calcium channel blockers like lercanidipine (LER), blocking "L" as well as "T-type" calcium activated channels, reduce intraglomerular pressure and urine protein excretion (UprotV) and also might stabilize renal function in several nephropathies.The main aim of this study was to compare the renoprotective efficacy of the addition of losartan (LOS) or LER to patients (Ps) with chronic kidney disease (CKD) receiving monotherapy with enalapril (ENL)... According to our results1. The addition of LER to standard therapy with ENL has similar renoprotective properties than ENL plus LOS.2. Adequate control of some modifiable (tobacco exposure) and/or non-modifiable conditions (DBT) may help reduce the risk of worsening renal function3."
Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hypertension • Metabolic Disorders • Nephrology • Renal Disease
March 28, 2024
Lercanidipine's Antioxidative Effect Prevents Noise-Induced Hearing Loss.
(PubMed, Antioxidants (Basel))
- "Based on these findings, we propose that lercanidipine has the capacity to alleviate NIHL and safeguard OHC survival in the basal turn, potentially via its antioxidative mechanism. These results suggest that lercanidipine holds promise as a clinically viable option for preventing NIHL in affected individuals."
Journal • Otorhinolaryngology
February 13, 2024
Lercanidipine ameliorated doxorubicin-induced neuroinflammation and maintained the expressions of choline acetyltransferase via enhancing the levels of PI3K/AKT/HIF1-α expressions.
(PubMed, Mol Biol Rep)
- "Both LRD doses reversed all these findings, but LRD2 was observed to be more effective. In conclusion, we determined that LRD has potential therapeutic effect by reducing DOX-induced neuroinflammation, oxidative stress and apoptosis in brain tissues."
Journal • Hematological Disorders • Inflammation • CASP3 • CHAT • HIF1A • IL10 • IL6 • PI3K
February 02, 2024
Effects of lercanidipine on traumatic spinal cord injury: an experimental study.
(PubMed, Ulus Travma Acil Cerrahi Derg)
- "Lercanidipine, a third-generation calcium channel blocker, is effective against inflammatory responses induced in spinal cord injury. Further studies are required to determine its capability in preventing apoptosis or improving functional recovery. To the best of our knowledge, this study is the first in the literature to examine the neuroprotective effects of lercanidipine on spinal cord injury."
Journal • CNS Disorders • Inflammation • Orthopedics
January 18, 2024
MELANOMA AND DYSPLASTIC NEVI DEVELOPMENT AFTER RANITIDINE/RILMENIDINE/МOXONIDINE, LERCANIDIPINE, ROSUVASTATIN AND VERAPAMIL/TRANDOLAPRIL - NEW DATA/CASE SERIES. THE POTENTIAL ROLE OF NITROSAMINE/NDSRIS CONTAMINATION IN POLYMEDICATION AS SUBSTANTIAL SKIN CANCER TRIGGERING FACTOR.
(PubMed, Georgian Med News)
- "In the last decade, melanoma has been described repeatedly in the medical literature as a possible side-effect within the intake of possibly with nitrosamines contaminated medications such as: Valsartan, Hydrochlorothiazide, Amlodipine, Nebivolol, Bisoprolol and Perindopril. Ingredients that are present in drug preparations, identified as availability and as carcinogenic potency, but not yet reflected in packaging or prescriptions. The question remains: why?"
Journal • Cutaneous Melanoma • Genetic Disorders • Melanoma • Oncology • Skin Cancer • Solid Tumor
November 22, 2023
NITROSOGENESIS LESSONS FROM DERMATOLOGISTS-NITROSAMINES/ NDSRIS CONTAMINATION OF THE POLIMEDICATION IN POLIMORBID PATIENTS AS THE MOST POWERFUL SKIN CANCER INDUCTOR: DOUBLE HATCHET FLAP FOR SCC OF THE SCALP OCCURRING DURING TREATMENT WITH VALSARTAN/ HYDROCHLOROTHIAZIDE AND LERCANIDIPINE.
(PubMed, Georgian Med News)
- "Discovering the logical relationship between databases (concerning the incidence of skin cancer, but not only) from different periods should only be relative or consistent with current bulletins of regulators and contaminated polymedication. This is what guarantees that the objective truth will be brought to the surface and ensure, through the possible rapid elimination of the contaminants: 1) better survival for patients and 2) better quality of life."
Journal • Cardiovascular • Dermatology • Genetic Disorders • Hypertension • Non-melanoma Skin Cancer • Oncology • Pulmonary Arterial Hypertension • Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer
October 05, 2023
Lercanidipine distribution in warm-blooded animals
(PubMed, Sud Med Ekspert)
- "The methods were validated by criteria of linearity, selectivity, accuracy, precision, detection limits and quantitative determination. The main content of lercanidipine (mg/100 g) was determined in the stomach content (198.183±29.541), the stomach (195.312±21.579), the small intestine (47.096±3.947), the spleen (38.952±3.532) and the liver (26.211±2.232)."
Journal
1 to 25
Of
107
Go to page
1
2
3
4
5